NEBCIN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jun 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEBCIN is an injectable small-molecule antibiotic approved by the FDA in 1979, likely a aminoglycoside based on naming conventions and route of administration. The drug is used to treat bacterial infections and is administered via injection. It represents a legacy antibiotic product from Eli Lilly's historical portfolio.
LOE Approaching
Declining revenue trajectory with minimal linked job openings suggests a legacy product with limited career growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEBCIN offers minimal career growth given zero linked job openings and approaching loss of exclusivity. Roles on this product are primarily maintenance-focused, managing a mature, generic-threatened portfolio asset with limited innovation or expansion potential.
Sales RepresentativeProduct Manager
Worked on NEBCIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.